RVMD catalysts
Catalysts and events linked to RVMD, newest first.
RVMD stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM 2026-09-03 · Up | clinical pipeline validation and increased regulatory approval probability | NEJM publication showed 42% ORR and 16.0 months median OS for daraxonrasib in RAS mutant NSCLC. | Not recorded |
| NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data 2026-09-03 · Up | clinical pipeline de-risking and commercial asset valuation | NEJM publication showed 42% ORR and 16.0 months median OS in NSCLC trial. | Not recorded |
| NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer 2026-09-03 · Up | clinical asset de-risking and pipeline revaluation | NEJM published Phase 1/2 data showing 42% ORR and 16.0 months median OS for daraxonrasib. | Not recorded |
| NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival 2026-09-03 · Up | clinical pipeline de-risking boosting biotechnology valuation | NEJM publication of Phase 1/2 daraxonrasib trial showing 42% ORR and 16.0 months median OS. | Not recorded |
| Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM 2026-09-03 · Up | clinical pipeline de-risking and addressable market validation | NEJM publication showed 42% ORR and 16.0 months median OS in RAS mutant NSCLC. | Not recorded |
| NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC 2026-09-03 · Up | clinical pipeline de-risking following peer-reviewed NEJM publication | NEJM published Phase 1/2 data showing 42% ORR and 16.0 months median OS for RASONQUE. | Not recorded |
| Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR 2026-09-03 · Up | pipeline clinical validation derisking regulatory approval pathway | NEJM publication showed 42% ORR and 16.0 months median overall survival in NSCLC. | Not recorded |
| FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer 2026-08-27 · Up | oncology product commercial revenue realization | FDA approved RASONQUE for metastatic pancreatic adenocarcinoma based on Phase 3 trial. | Not recorded |
Do these developments change your position?
Review RVMD alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLCRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer DataRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORRRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo SurvivalRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLCRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung CancerRVMD
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic CancerRVMD
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic CancerRVMD
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE as First Broad RAS InhibitorIMRX RVMD
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic CancerRVMD
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic CancerIMRX RVMD
- 2026-08-27FDA Approves Revolution Medicines RASONQUE in Pancreatic CancerRVMD
- 2026-08-27FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic AdenocarcinomaIMRX RVMD
- 2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS InhibitorRVMD XBI-1.79%
- 2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS InhibitorRVMD XBI-1.79%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.